DESIGN, DEVELOPMENT, AND EVALUATION OF CHITOSAN MATRIX-BASED SUSTAINABLE TRANSDERMAL DRUG DELIVERY SYSTEM

Abstract

The object behind the work is to formulate and characterize a transdermal patch of diclofenac sodium. Diclofenac sodium (DS) associated with the low bioavailability, short half-life and dose-related the adverse effect. To overcome these problems transdermal patch of diclofenac sodium was investigated. The matrix type transdermal patch of diclofenac sodium was design by the solvent evaporation method using chitosan as a polymer with propylene glycol as permeation enhancer and glycerol as a plasticizer. The prepared system was characterized for physicochemical properties, in-vitro release studies, ex-vivo permeation study, stability, irritation study and anti-inflammatory activity. In optimized patch FP3 (Chitosan 400 mg), drug content was found to be 94.51±0.73% and 83.36±0.84 % drug was released in 48 h. The exvivo study on excised rat abdominal skin showed the sustained drug permeation (54.3609%) in 24 h. Optimized formulation was safe, effective and devoid of dermal sensatization. The results of the anti-inflammatory activity, patches applied before 2 h of carrageenan injection showed 76.13±0.16% inhibition of inflammation whereas 100±0.01% inhibition of inflammation within 24 h of carrageenan insult when patches applied before 12 h of carrageenan insult. Transdermal patch has a greater potential to sustain its release characteristics.